摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-丁二醇单乙酸酯 | 35435-68-8

中文名称
1,4-丁二醇单乙酸酯
中文别名
——
英文名称
1,4-Butanediol, monoacetate
英文别名
acetic acid;butane-1,4-diol
1,4-丁二醇单乙酸酯化学式
CAS
35435-68-8
化学式
C6H14O4
mdl
——
分子量
150.17
InChiKey
XXGZPUCDKOQDDL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    80 °C(Press: 2 Torr)
  • 密度:
    1.0425 g/cm3
  • 溶解度:
    可溶于DMSO(轻微)、甲醇(轻微、加热)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.16
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    77.8
  • 氢给体数:
    3
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2915390090

SDS

SDS:4167b26d1f3be75ad250f653dc6b5058
查看

文献信息

  • Method for the preparation of organic nitrates
    申请人:Lonza AG
    公开号:EP2048129A1
    公开(公告)日:2009-04-15
    The present invention relates to a process for the preparation of organic nitrates having at least one nitryloxy and at least one hydroxy group, wherein the at least one hydroxy group may be present in form of an esterified hydroxy residue, the latter being esterified with an acid other than nitric acid.
    本发明涉及一种制备具有至少一个硝基氧基和至少一个羟基的有机硝酸酯的方法,其中至少一个羟基可以以酯化羟基残基的形式存在,后者与除硝酸以外的酸酯化。
  • 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof
    申请人:Averett R. Devron
    公开号:US20050070556A1
    公开(公告)日:2005-03-31
    The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    这项发明涉及3-β-D-核糖呋喃噻唑并[4,5-d]吡啶嘧啶核苷及含有这种化合物的具有免疫调节活性的药物组合物。该发明还涉及这种化合物和组合物的治疗或预防用途,以及通过给予这种化合物的有效量来治疗本文描述的疾病和紊乱的方法。
  • [EN] 3-beta-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF<br/>[FR] NUCLEOSIDES 3-20051222WO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605WX1-20XUS5041426AROBINS ROLAND K [US], et al19910820compounds 6,7,41,42X1,2,12XWO03045968A1ANADYS PHARMACEUTICALS INC [US]20030605"Remington's Pharmaceutical Sciences"Remington's Pharmaceutical SciencesBARANOV ET AL., CHEM. HET. COMPOUNDS, vol. 11, 1975, pages 73BARANOV ET AL.CHEM. HET. COMPOUNDS19751173
    申请人:ANADYS PHARMACEUTICALS INC
    公开号:WO2005121162A1
    公开(公告)日:2005-12-22
    The invention is directed to 3-ß-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    本发明涉及3-ß-D-核糖呋喃噻唑[4,5-d]吡啶嘧啶核苷和含有此类化合物的药物组合物,具有免疫调节活性。本发明还涉及这类化合物和组合物的治疗或预防用途,以及通过给予这类化合物的有效剂量来治疗本文所述的疾病和疾病的方法。
  • PROCESS FOR PREPARING 1,4-BUTANDIOL MONITRATE
    申请人:Hack Achim
    公开号:US20100137599A1
    公开(公告)日:2010-06-03
    The present invention relates to a process for the preparation of 1,4-butanediol mononitrate as intermediate for large scale preparation of high purity nitrooxybutyl ester of pharmaceutically active compounds.
    本发明涉及一种制备1,4-丁二醇硝酸酯的方法,作为制备高纯度药用活性化合物硝氧基丁酯的中间体的大规模制备。
  • 3-Beta-D-Ribofuranosylthiazolo&lsqb; 4,5-D&rsqb; Pyridimine Nucleosides and Uses Thereof
    申请人:Averett Devron R.
    公开号:US20080070852A1
    公开(公告)日:2008-03-20
    The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    本发明涉及3-β-D-核糖呋喃噻唑[4,5-d]嘧啶核苷及含有这种化合物的药物组合物,其具有免疫调节活性。本发明还涉及使用这种化合物和组合物进行治疗或预防,以及通过给予有效剂量的这种化合物来治疗本文所述的疾病和障碍的方法。
查看更多